Skip to main content
Top

01-01-2016 | Systemic lupus erythematosus | Book Chapter | Article

68. Systemic Lupus Erythematosus

Authors: Edoardo Baglivo, MD, Camillo Ribi, MD

Publisher: Springer Berlin Heidelberg

Abstract

Systemic lupus erythematosus is a chronic inflammatory disorder with a wide range of clinical manifestations and profound immunologic disturbances. It is characterized by the production of large quantities of autoantibodies. Its causes remain unknown. About 90 % of SLE patients are women, predominantly of childbearing age. The reported prevalence in the population ranges from 20 to 150 cases per 100,000. Geographic, ethnic, and socioeconomic factors influence disease frequency and expression. SLE generally appears to be more frequent and more severe in people of African and Asian descent. Estimated incidence ranges from 1 to 10 per 100,000 person-years. Incidence rates have increased in the past decades, probably due to improvements in diagnosis.
Literature
1.
Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH et al (1998) Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 41(5):778–799CrossRefPubMed
2.
Chakravarty EF, Bush TM, Manzi S, Clarke AE, Ward MM (2007) Prevalence of adult systemic lupus erythematosus in California and Pennsylvania in 2000: estimates obtained using hospitalization data. Arthritis Rheum 56(6):2092–2094PubMedCentralCrossRefPubMed
3.
Pons-Estel GJ, Alarcon GS, Scofield L, Reinlib L, Cooper GS (2010) Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum 39(4):257–268PubMedCentralCrossRefPubMed
4.
Uramoto KM, Michet CJ Jr, Thumboo J, Sunku J, O’Fallon WM, Gabriel SE (1999) Trends in the incidence and mortality of systemic lupus erythematosus, 1950–1992. Arthritis Rheum 42(1):46–50CrossRefPubMed
5.
Nasir S, Kerr DA, Birnbaum J (2009) Nineteen episodes of recurrent myelitis in a woman with neuromyelitis optica and systemic lupus erythematosus. Arch Neurol 66(9):1160–1163CrossRefPubMed
6.
Griffiths B, Mosca M, Gordon C (2005) Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. Best Pract Res Clin Rheumatol 19(5):685–708CrossRefPubMed
7.
Gold DH, Morris DA, Henkind P (1972) Ocular findings in systemic lupus erythematosus. Br J Ophthalmol 56(11):800–804PubMedCentralCrossRefPubMed
8.
Lanham JG, Barrie T, Kohner EM, Hughes GR (1982) SLE retinopathy: evaluation by fluorescein angiography. Ann Rheum Dis 41(5):473–478PubMedCentralCrossRefPubMed
9.
Ushiyama O, Ushiyama K, Koarada S, Tada Y, Suzuki N, Ohta A et al (2000) Retinal disease in patients with systemic lupus erythematosus. Ann Rheum Dis 59(9):705–708PubMedCentralCrossRefPubMed
10.
Laroche L, Saraux H (1984) Unilateral central retinal vein occlusion in systemic lupus erythematosus. Ophthalmologica 189(3):128–129CrossRefPubMed
11.
Jabs DA, Fine SL, Hochberg MC, Newman SA, Heiner GG, Stevens MB (1986) Severe retinal vaso-occlusive disease in systemic lupus erythematous. Arch Ophthalmol 104(4):558–563CrossRefPubMed
12.
Kremer I, Gilad E, Cohen S, Ben Sira I (1985) Combined arterial and venous retinal occlusion as a presenting sign of systemic lupus erythematosus. Ophthalmologica 191(2):114–118CrossRefPubMed
13.
Rappaport KD, Tang WM (2000) Herpes simplex virus type 2 acute retinal necrosis in a patient with systemic lupus erythematosus. Retina 20(5):545–546CrossRefPubMed
14.
Read RW, Chong LP, Rao NA (2000) Occlusive retinal vasculitis associated with systemic lupus erythematosus. Arch Ophthalmol 118(4):588–589CrossRefPubMed
15.
Khng CG, Yap EY, Au-Eong KG, Lim TH, Leong KH (2000) Central serous retinopathy complicating systemic lupus erythematosus: a case series. Clin Experiment Ophthalmol 28(4):309–313CrossRefPubMed
16.
Karpik AG, Schwartz MM, Dickey LE, Streeten BW, Roberts JL (1985) Ocular immune reactants in patients dying with systemic lupus erythematosus. Clin Immunol Immunopathol 35(3):295–312CrossRefPubMed
17.
Chan DQ (2000) Neurologic, ophthalmic, and neuropsychiatric manifestations of pediatric systemic lupus erythematosus. Optom Vis Sci 77(8):388–394CrossRefPubMed
18.
Levine SR, Welch KM (1987) The spectrum of neurologic disease associated with antiphospholipid antibodies. Lupus anticoagulants and anticardiolipin antibodies. Arch Neurol 44(8):876–883CrossRefPubMed
19.
Brandt KD, Lessell S, Cohen AS (1975) Cerebral disorders of vision in systemic lupus erythematosus. Ann Intern Med 83(2):163–169CrossRefPubMed
20.
McCune WJ, Golbus J (1988) Neuropsychiatric lupus. Rheum Dis Clin North Am 14(1):149–167PubMed
21.
Teoh SC, Yap EY, Au Eong KG (2001) Neuro-ophthalmological manifestations of systemic lupus erythematosus in Asian patients. Clin Experiment Ophthalmol 29(4):213–216CrossRefPubMed
22.
Chen YC, Cheng TT, Lai HM, Wu CH (2000) Overwhelming septic cavernous sinus thrombosis in a woman after combination of high-dose steroid and intravenous cyclophosphamide therapy for lupus nephritis. Lupus 9(1):78–79CrossRefPubMed
23.
Fossaluzza V, Dal Mas P (1987) Proptosis and systemic lupus erythematosus. Clin Exp Rheumatol 5(2):192–193PubMed
24.
Johnson MW, Vine AK (1987) Hydroxychloroquine therapy in massive total doses without retinal toxicity. Am J Ophthalmol 104(2):139–144CrossRefPubMed
25.
Okada AA (2005) Immunomodulatory therapy for ocular inflammatory disease: a basic manual and review of the literature. Ocul Immunol Inflamm 13(5):335–351CrossRefPubMed
26.
Deapen D, Escalante A, Weinrib L, Horwitz D, Bachman B, Roy-Burman P et al (1992) A revised estimate of twin concordance in systemic lupus erythematosus. Arthritis Rheum 35(3):311–318CrossRefPubMed
27.
Bussone G, Mouthon L (2009) Autoimmune manifestations in primary immune deficiencies. Autoimmun Rev 8(4):332–336CrossRefPubMed
28.
Crow MK (2009) Developments in the clinical understanding of lupus. Arthritis Res Ther 11(5):245PubMedCentralCrossRefPubMed
29.
Scofield RH, Bruner GR, Namjou B, Kimberly RP, Ramsey-Goldman R, Petri M et al (2008) Klinefelter’s syndrome (47, XXY) in male systemic lupus erythematosus patients: support for the notion of a gene-dose effect from the X chromosome. Arthritis Rheum 58(8):2511–2517PubMedCentralCrossRefPubMed
30.
Poole BD, Templeton AK, Guthridge JM, Brown EJ, Harley JB, James JA (2009) Aberrant Epstein-Barr viral infection in systemic lupus erythematosus. Autoimmun Rev 8(4):337–342PubMedCentralCrossRefPubMed
31.
Lehmann P, Homey B (2009) Clinic and pathophysiology of photosensitivity in lupus erythematosus. Autoimmun Rev 8(6):456–461CrossRefPubMed
32.
Vittecoq O, Lequerre T, Goeb V, Le Loet X, Abdesselam TA, Klemmer N (2008) Smoking and inflammatory diseases. Best Pract Res Clin Rheumatol 22(5):923–935CrossRefPubMed
33.
Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA et al (2003) Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 349(16):1526–1533CrossRefPubMed
34.
Kowal C, DeGiorgio LA, Nakaoka T, Hetherington H, Huerta PT, Diamond B et al (2004) Cognition and immunity; antibody impairs memory. Immunity 21(2):179–188CrossRefPubMed
35.
Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25(11):1271–1277CrossRefPubMed
36.
Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40(9):1725CrossRefPubMed
37.
Petri M, Orbai AM, Alarcon GS, Gordon C, Merrill JT, Fortin PR et al (2012) Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64(8):2677–2686PubMedCentralCrossRefPubMed
38.
Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT et al (2005) Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 353(21):2219–2228CrossRefPubMed
39.
Miescher PA (1986) Treatment of systemic lupus erythematosus. Springer Semin Immunopathol 9(2–3):271–282CrossRefPubMed
40.
Baker KP, Edwards BM, Main SH, Choi GH, Wager RE, Halpern WG et al (2003) Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum 48(11):3253–3265CrossRefPubMed
41.
Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzova D et al (2011) A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 63(12):3918–3930CrossRefPubMed
42.
Nguyen QD, Uy HS, Akpek EK, Harper SL, Zacks DN, Foster CS (2000) Choroidopathy of systemic lupus erythematosus. Lupus 9(4):288–298CrossRefPubMed
43.
Ginzler EM, Schorn K (1988) Outcome and prognosis in systemic lupus erythematosus. Rheum Dis Clin North Am 14(1):67–78PubMed
44.
Lam GK, Petri M (2005) Assessment of systemic lupus erythematosus. Clin Exp Rheumatol 23(5 Suppl 39):S120–S132PubMed
45.
Sternberg AD (1992) Systemic lupus erythematosus. In: Wyngaarden JB, Smith LH, Bennett JC (eds) Cecil textbook of medicine, 19th edn. WB Saunders, Philadelphia, p 1526
46.
Hahn BH (2008) Systemic lupus erythematosus. In: Fauci AS et al (eds) Harrison’s principles of internal medicine, 17th edn. McGraw-Hill, New York, p 2076
47.
Rahman A, Isenberg DA (2008) Systemic lupus erythematosus. N Engl J Med 358:929–939 (931)CrossRefPubMed
48.
Foster CS, Sobrin L (2008) Systemic lupus erythematosus. In: Albert DM, Miller JW, Azar DT (eds) Albert & Jakobiec’s principles & practice of ophthalmology. W B Saunders, Philadelphia, pp 4429–4434CrossRef